Purdue Pharma LP, of Stamford, Conn., plans to acquire Spinethera Inc., of Plymouth, Minn., to gain access to Spinethera's products and technology platforms, including its lead asset, SX-600, a microsphere suspension of dexamethasone being developed as an epidural administration for low back pain. Terms of the deal weren't disclosed.